
News|Articles|March 1, 2008
FDA pipeline preview, March 2008
FDA-related information through March 2008 on C1 inhibitor, ferric carboxymaltose injection, lovastatin, carbidopa/levodopa extended release, vigabatrin, bortezomib, peginterferon alfa-2b, elesclomol, triphendiol, VQD-002
Advertisement
Complete response letter
Recommended for approval
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
WHO Global Report on Antimicrobial Resistance Sheds Light on Growing Threat
4
Sponsored: The Teva Biosimilars Trend Report
5